Press Releases

Today, the House Judiciary Committee unanimously passed four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. This markup is part of the first phase of the Committee's agenda to lower the soaring cost of prescription drugs.

Washington, D.C. (April 30, 2019) – Today, Representatives Elijah E. Cummings (D-MD), Chairman of the Committee on Oversight and Reform; Jerrold Nadler (D-NY), Chairman of the House Committee on the Judiciary; and Karen Bass (D-CA), Chairwoman of the Subcommittee on Crime, Terrorism and Homeland Security; reintroduced the Record Expungement Designed to Enhance Employment (REDEEM) Act on the last day of Second Chance Month. U.S. Senator Cory Booker (D-NJ) plans to reintroduce the bill in the Senate in the coming weeks.

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act):

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2376, the Prescription Pricing for the People Act of 2019:

"H.R. 2376, the 'Prescription Pricing for the People Act of 2019,' would require the Federal Trade Commission to conduct a comprehensive report on the state of competition in the drug supply chain.

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act):

"H.R. 965, the 'Creating and Restoring Equal Access to Equivalent Samples Act of 2019,' or the 'CREATES Act,' is bipartisan legislation that would substantially lower drug prices by making it easier for generic pharmaceutical companies to obtain drug samples from branded companies, which they require in order to perform testing necessary to enter the market.

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act:

"H.R. 2375, the 'Preserve Access to Affordable Generics and Biosimilars Act' is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring cost of prescription drugs, which is jeopardizing the health and well-being of millions of Americans.

In a victory for Members of Congress, Judge Emmet Sullivan of the U.S. District Court for the District of Columbia has now denied, in full, President Trump's motion to dismiss the challenge brought by roughly 200 Members of the Senate and House of Representatives, to hold him accountable to the Constitution's Foreign Emoluments Clause. On learning this news, the lead plaintiffs and their counsel issued the following statement: